Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractThe presence of small amounts of tumor DNA in cell free DNA (CFDNA) circulating in the plasma or serum of cancer patients was first demonstrated 30 years ago. Since then, overall plasma DNA concentration in cancer patients and genetic or epigenetic alterations specific to tumor DNA have been investigated in patients diagnosed with different types of cancer. The proportion of patients with altered CFDNA varies with the pathology and the nature of the marker. However, several studies have reported the presence of altered CFDNA in over 50% of cancer patients, suggesting that this marker may be common and amenable for a variety of clinical and epidemiological studies. Because the mechanisms and timing of CFDNA release in the blood stream are poorly understood, only few studies have addressed the use of CFDNA for early cancer detection or as a biomarker for mutagenesis and tumourigenesis in molecular epidemiology. In this review, we discuss the technical issues involved in obtaining, using and analyzing CFDNA in cancer or healthy subjects. We also summarize the literature available on the mechanisms of CDNA release as well as on cross-sectional or prospective studies aimed at assessing the clinical and biological significance of CFDNA. These studies show that, in some circumstances, CFDNA alterations are detectable ahead of cancer diagnosis, raising the possibility of exploiting them as biomarkers for monitoring cancer occurrence. Testing these hypotheses will require well-designed studies, assessing multiple markers with quantitative and sensitive methods, with adequate follow-up of subjects, and we provide recommendations for the development of such studies.
CitationMutat. Res. 635 (2-3):105-117
Sponsorshe authors of this paper are partners of European Cancer Risk, Nutrition and Individual Susceptibility (ECNIS), a network of excellence operating within the European Union 6th Framework Program, Priority 5: “Food Quality and Safety” (Contract No. 513943). The work on plasma DNA at IARC was partially supported by the Compagnia di San Paolo (Torino, Italy), the Lega Italiana per la lotta contro I tumori and the European Community (GENAIR programme, QL4-1999-000927).
- A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
- Authors: Thierry AR
- Issue date: 2016
- Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
- Authors: Spindler KG
- Issue date: 2017 Jan
- [Characteristics and diagnostic applications of circulating cell-free DNA in colorectal cancer].
- Authors: Barták BK, Márkus E, Kalmár A, Galamb O, Szigeti K, Nagy ZB, Zsigrai S, Tulassay Z, Dank M, Igaz P, Molnár B
- Issue date: 2019 Jul
- Circulating free DNA in a screening program for early colorectal cancer detection.
- Authors: Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni E, Leo E, Pierotti MA, Pilotti S
- Issue date: 2014 Mar-Apr
- Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
- Authors: Mazurek AM, Fiszer-Kierzkowska A, Rutkowski T, Składowski K, Pierzyna M, Scieglińska D, Woźniak G, Głowacki G, Kawczyński R, Małusecka E
- Issue date: 2013